Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy. METHODS: We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) or placebo every 2 weeks for up to 12 months. The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy. The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim analysis). Secondary end points included 12-month and 18-month progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety. RESULTS: Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo). The median progression-free survival from randomization was 16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months). The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 months vs. 14.6 months; P<0.001). Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, respectively). A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events. CONCLUSIONS: Progression-free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical benefi t with maintenance ICT in specifi c settings was demonstrated in patients with nonsmall cell lung cancer (NSCLC; ref.50 ), extensive-stage small cell lung cancer ( 51,52 ), and bladder cancer ( 53 ), leading to FDA approvals in these tumor types.”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [50]
In the citing paper
“By contrast, ICB has shown promise in the adjuvant setting in patients with melanoma or NSCLC57–59”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Bradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., Bogart, J., Hu, C., Forster, K., Magliocco, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71207-0 · Cited by 2,015
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,878
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,313
Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H. M., Crowley, J. J., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4824 · Cited by 573
Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., Nawrocki, S., Ciuleanu, T.-E., Bosquée, L., Trigo, J. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 538
Hanna, N., Neubauer, M., Yiannoutsos, C., McGarry, R., Arseneau, J., Ansari, R., Reynolds, C., Govindan, R., Melnyk, A., Fisher, W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7840 · Cited by 491
Vansteenkiste, J., De Ruysscher, D., Eberhardt, W. E. E., Lim, E., Senan, S., Felip, E., & Peters, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt241 · Cited by 490
Research works printed but not linked: 1
- Ettinger S, Wood DE, Aisner DL, et al. Non-small cell lung cancer, Version 5.2017. J Natl Compr Canc Netw 2017; 15: 504-35.
Cited by
Items 601–700 of 1,008
Li, Q., Wu, X., Guo, L., Shi, J., & Li, J. (2019) · FEBS Open Bio · doi:10.1002/2211-5463.12738 · Cited by 59
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
Berghmans, T., Durieux, V., Hendriks, L. E. L., & Dingemans, A. C. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.00090 · Cited by 62
Xing, L., Wu, G., Wang, L., Li, J., Wang, J., Yuan, Z., Chen, M., Xu, Y., Fu, X., Zhu, Z., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.11.026 · Cited by 63
Tian, Y., Zhai, X., Yan, W., Zhu, H., & Yu, J. (2020) · Cancer Medicine · doi:10.1002/cam4.3590 · Cited by 61
Stares, M., Ding, T.-E., Stratton, C., Thomson, F., Baxter, M. A., Cagney, H. P., Cumming, K., Swan, A. M., Ross, F., Barrie, C., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100445 · Cited by 71
Shen, D., Wang, J., Wu, J., Chen, S., Li, J., Liu, J., Chen, Q., & Jiang, Y. (2021) · Journal of Thoracic Disease · doi:10.21037/jtd-21-103 · Cited by 62
Riudavets, M., Auclin, É., Mosteiro, M., Dempsey, N. G., Majem, M., Lobefaro, R., Castro, R. L., Bosch‐Barrera, J., Pilotto, S., Escalera, E., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.02.014 · Cited by 63
Self-citationLuo, R., Onyshchenko, K., Wang, L., Gaedicke, S., Grosu, A., Firat, E., & Niedermann, G. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1591 · Cited by 63
Barlési, F., Cho, B. C., Goldberg, S. B., Yoh, K., Gelatti, A. C. Z., Mann, H., Gopinathan, A., Bielecka, Z. F., Newton, M., & Aggarwal, C. (2024) · Future Oncology · doi:10.1080/14796694.2024.2354160 · Cited by 65
Self-citationClinical development of immuno-oncology therapeutics
Wang, J., Chen, Q., Shan, Q., Liang, T., Forde, P. M., & Zheng, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217616 · Cited by 61
Targeting immune checkpoints in non small cell lung cancer
Bianco, A., Malapelle, U., Rocco, D., Perrotta, F., & Mazzarella, G. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.02.006 · Cited by 59
Immuno-oncology-101: overview of major concepts and translational perspectives
Allard, B., Aspeslagh, S., Garaud, S., Dupont, F., Solinas, C., Kok, M., Routy, B., Sotiriou, C. P., Stagg, J., & Buisseret, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.005 · Cited by 68
Li, Y. D., Lamano, J. B., Lamano, J. B., Quaggin-Smith, J. A., Veliceasa, D., Kaur, G., Biyashev, D., Unruh, D. J., & Bloch, O. G. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02384-y · Cited by 58
Miura, Y., Mouri, A., Kaira, K., Yamaguchi, O., Shiono, A., Hashimoto, K., Nishihara, F., Shinomiya, S., Akagami, T., Murayama, Y., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13394 · Cited by 61
Friedes, C., Chakrabarti, T., Olson, S., Prichett, L. M., Brahmer, J. R., Forde, P. M., Voong, K. R., Marrone, K. A., Lam, V. K. L., Hann, C. L., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.01.022 · Cited by 67
PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines
Safi, M., Ahmed, H., Al‐Azab, M., Xia, Y., Shan, X., Alradhi, M., Al-Danakh, A., Shopit, A., & Liu, J. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.09.006 · Cited by 61
Shintani, T., Kishi, N., Matsuo, Y., Ogura, M., Mitsuyoshi, T., Araki, N., Fujii, K., Okumura, S., Nakamatsu, K., Kishi, T., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.01.017 · Cited by 58
Self-citationDeschênes‐Simard, X., Richard, C., Galland, L., Blais, F., Desîlets, A., Malo, J., Cvetkovic, L., Belkaïd, W., Elkrief, A., Gagné, A., et al. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.06.018 · Cited by 57
Li, M., Liu, D., Lee, D., Cheng, Y., Baumhover, N. J., Marks, B. M., Sagastume, E. A., Ballas, Z. K., Johnson, F. L., Morris, Z. S., et al. (2021) · Cancers · doi:10.3390/cancers13153676 · Cited by 60
Neoadjuvant immunotherapy for resectable esophageal cancer: A review
Li, Q., Liu, T., & Ding, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1051841 · Cited by 57
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
García-Martínez, E., Smith, M. M., Buqué, A., Aranda, F., de la Peña, F. A., Rubio, A. I., Cánovas, M. S., Conesa, M. A. V., Fucikova, J. P., Špíšek, R., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433982 · Cited by 59
Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
Lee, L. J., & Matulonis, U. A. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.03.255 · Cited by 59
Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors
Grywalska, E., Sobstyl, M., Putowski, L. T., & Roliński, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194705 · Cited by 61
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors
Gravbrot, N., Gilbert-Gard, K., Mehta, P. P., Ghotmi, Y., Banerjee, M., Mazis, C. M., & Sundararajan, S. (2019) · Antibodies · doi:10.3390/antib8040051 · Cited by 62
Bando, H., Kotani, D., Tsushima, T., Hara, H., Kadowaki, S., Kato, K., Chìn, K., Yamaguchi, K., Kageyama, S., Hojo, H., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06716-5 · Cited by 64
Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore
Li, R., Han, D., Shi, J., Han, Y., Tan, P., Zhang, R., & Li, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188420 · Cited by 67
de Mello, R. A., Neves, N. M., Tadokoro, H., Amaral, G. A., Castelo‐Branco, P., & Zia, V. A. D. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113543 · Cited by 62
Therapeutic applications of the cancer immunoediting hypothesis
Desai, R. R., Coxon, A. T., & Dunn, G. P. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.002 · Cited by 59
Cheng, B., Xiao, Y., Xue, M., Cao, H., & Chen, J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01362 · Cited by 56
Ling, Y., Li, N., Li, L., Guo, C., Wei, J., Yuan, P., Tan, F., Tao, X., Wang, S., Wang, Z., et al. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00135-2 · Cited by 62
Jazieh, A. R., Önal, C., Tan, D. S. W., Soo, R. A., Prabhash, K., Kumar, A., Huggenberger, R., Robb, S., & Cho, B. C. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.05.003 · Cited by 63
Self-citationPark, S., Sun, J., Choi, Y., Oh, D., Kim, H. K., Lee, T., Chi, S., Lee, S.-H., Choi, Y. S., Jung, S., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100385 · Cited by 60
Liang, F., Wang, G., Wang, Y., Yang, Y., Wen, Z., Chen, D. S., Fang, W., Zhang, B., Yang, L., Zhang, C., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01127-3 · Cited by 61
Predicting Radiation-Induced Lung Injury in Patients With Lung Cancer: Challenges and Opportunities
Kuipers, M. E., Wink, K. C. J., Hiemstra, P. S., & Slats, A. M. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.10.044 · Cited by 63
HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer
Deng, R., Zhang, P., Liu, W., Zeng, X., Ma, X., Shi, L., Wang, T., Yin, Y., Chang, W., Zhang, P., et al. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0589-6 · Cited by 56
Boothman, A.-M., Scott, M. L. J., Ratcliffe, M., Whiteley, J. L., Dennis, P. A., Wadsworth, C., Sharpe, A. D., Rizvi, N. A., Garassino, M. C., & Walker, J. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.04.025 · Cited by 56
Self-citationQiu, B., Li, Q., Liu, J., Huang, Y., Pang, Q., Zhu, Z., Yang, X., Wang, B., Chen, L., Fang, J., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.05.003 · Cited by 55
Self-citationBuchberger, D. S., & Videtic, G. M. M. (2023) · JCO Oncology Practice · doi:10.1200/op.22.00475 · Cited by 62
Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
Mina, L. A., Lim, S., Bahadur, S. W., & Firoz, A. T. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s184710 · Cited by 66
Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents
Singh, T., Hassanabad, M. F., & Hassanabad, A. F. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188636 · Cited by 62
Jazieh, K., Khorrami, M., Saad, A. M., Gad, M. M., Gupta, A. B., Patil, P. D., Viswanathan, V. S., Rajiah, P. S., Nock, C. J., Gilkey, M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003778 · Cited by 60
Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021
Benjamin, D. J., Xu, A., Lythgoe, M. P., & Prasad, V. K. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.2265 · Cited by 57
Strategies to overcome DC dysregulation in the tumor microenvironment
Mestrallet, G., Sone, K., & Bhardwaj, N. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.980709 · Cited by 57
Immunotherapy-related biomarkers: Confirmations and uncertainties
Catalano, M., Iannone, L. F., Nesi, G., Nobili, S., Mini, E., & Roviello, G. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104135 · Cited by 71
Yang, Y., Pang, K., Lin, G., Liu, X., Gao, J., Zhou, J., Xu, L., Gao, Z., Wu, Y., Li, A., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03360-5 · Cited by 58
Cancer therapy-induced cardiotoxicity: mechanisms and mitigations
Shil, S., Kumar, P., & Mumbrekar, K. D. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10531-0 · Cited by 64
Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma
Wisdom, A. J., Mowery, Y. M., Riedel, R. F., & Kirsch, D. G. (2018) · Cancer · doi:10.1002/cncr.31517 · Cited by 54
Immunotherapy in the Asiatic population: any differences from Caucasian population?
Peng, L.-X., & Wu, Y.-L. L. C. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.106 · Cited by 61
Petrelli, F., Ghidini, A., Cabiddu, M., Tomasello, G., Stefani, A. D., Bruschieri, L., Vitali, E., Ghilardi, M., Borgonovo, K., Barni, S., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.017 · Cited by 54
Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle
Wattenberg, M. M., & Beatty, G. L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.002 · Cited by 59
Li, T., Pan, S., Zhuang, H., Gao, S., & Xu, H. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b01172 · Cited by 56
Immune biological rationales for the design of combined radio- and immunotherapies
Hader, M., Frey, B., Fietkau, R., Hecht, M., & Gaipl, U. S. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02460-3 · Cited by 60
Weiss, J. M., Sheth, S. H., Deal, A. M., Grilley‐Olson, J. E., Patel, S. N., Hackman, T., Blumberg, J. M., Galloway, T. J., Patel, S. A., Zanation, A. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0230 · Cited by 54
Christie, J. R., Lang, P., Zelko, L. M., Palma, D. A., Abdelrazek, M., & Mattonen, S. A. (2020) · Canadian Association of Radiologists Journal · doi:10.1177/0846537120941434 · Cited by 62
Popat, S., Navani, N., Kerr, K. M., Smit, E. F., Batchelor, T. J. P., Schil, P. E. V., Senan, S., & McDonald, F. (2020) · The Oncologist · doi:10.1002/onco.13586 · Cited by 61
Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer
Limited, O. B. O. A. U., & Conibear, J. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01070-6 · Cited by 56
Maghrouni, A., Givari, M., Jalili‐Nik, M., Mollazadeh, H., Bibak, B., Sadeghi, M. M., Afshari, A. R., Johnston, T. P., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107403 · Cited by 61
Makunts, T., Saunders, I. M., Cohen, I. V., Li, M., Moumedjian, T., Issa, M. A., Burkhart, K., Lee, P., Patel, S. P., & Abagyan, R. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-96467-5 · Cited by 59
Tunali, I., Tan, Y. Q., Gray, J. E., Katsoulakis, E., Eschrich, S. A., Saller, J. J., Aerts, H. J. W. L., Boyle, T. A., Qi, J., Güveniş, A., et al. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkab048 · Cited by 55
Self-citationNanomedicine in Lung Cancer Immunotherapy
Doroudian, M., Zanganeh, S., Abbasgholinejad, E., & Donnelly, S. C. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1144653 · Cited by 55
Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities
Guha, A., Armanious, M. A., & Fradley, M. G. (2018) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2018.06.001 · Cited by 56
Pu, X., Wu, L., Su, D., Mao, W., & Fang, B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4990-5 · Cited by 58
Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients
Sridhar, S., Paz-Ares, L. G., Liu, H., Shen, K., Morehouse, C., Rizvi, N. A., Segal, N. H., Jin, X., Zheng, Y., Narwal, R., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.06.020 · Cited by 53
Self-citationAdvances in Engineering Cells for Cancer Immunotherapy
Xu, X., Li, T., Shen, S., Wang, J., Abdou, P., Gu, Z., & Mo, R. (2019) · Theranostics · doi:10.7150/thno.38583 · Cited by 56
Tsukui, H., Horie, H., Koinuma, K., Ohzawa, H., Sakuma, Y., Hosoya, Y., Yamaguchi, H., Yoshimura, K., Lefor, A. K., Sata, N., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06893-3 · Cited by 57
Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy
Benítez, J. C., Remón, J., & Besse, B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3255 · Cited by 60
Hung, H.-Y., Tseng, Y.-H., Chao, H., Chiu, C., Hsu, W., Hsu, H., Wu, Y., Chou, T., Chen, C.-K., Lan, K.-L., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0236503 · Cited by 63
Ke, M., Xu, T., Fang, Y., Ye, Y., Li, Z.-J., Ren, F., Lu, S., Zhang, X., Wu, R., Lv, Y., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.05.007 · Cited by 55
Wang, Q., Zeng, A., Zhu, M., & Song, L. (2023) · International Journal of Oncology · doi:10.3892/ijo.2023.5474 · Cited by 61
Desai, A. P., & Lovly, C. M. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-708 · Cited by 59
The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis—From Conception to Treatment
Weichselbaum, R. R. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00847 · Cited by 55
Foster, C. C., Sher, D. J., Rusthoven, C. G., Verma, V., Spiotto, M. T., Weichselbaum, R. R., & Koshy, M. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1222-3 · Cited by 54
New advances in immunotherapy for non-small cell lung cancer.
Qin, H., Wang, F., Liu, H., Zeng, Z., Wang, S., Pan, X. H., & Gao, H. (2018) · Europe PMC (PubMed Central) · Cited by 53
Abscopal Effect in Lung Cancer: Three Case Reports and a Concise Review
Garelli, E., Rittmeyer, A., Putora, P. M., Glatzer, M., Dressel, R., & Andreas, S. (2019) · Immunotherapy · doi:10.2217/imt-2019-0105 · Cited by 59
O’Hara, M. H., Messersmith, W. A., Kindler, H. L., Zhang, W., Pitou, C., Szpurka, A. M., Wang, D., Peng, S.-B., Vangerow, B., Khan, A. A., et al. (2020) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2019.0018 · Cited by 55
Chen, J., Zhou, Z., Zheng, C., Liu, Y., Hao, R., Ji, X., Xi, Q., Shen, J., & Li, Z. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118869 · Cited by 53
Park, S., Joung, J., Min, Y. W., Nam, J., Ryu, D., Oh, D., Park, W., Lee, S. K., Choi, Y., Ahn, J. S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0609-x · Cited by 57
Bruni, A., Scotti, V., Borghetti, P., Vagge, S., Cozzi, S., D’Angelo, E., Giaj‐Levra, N., Fozza, A., Taraborrelli, M., Piperno, G., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.744956 · Cited by 67
Craddock, M., Nestle, U., Koenig, J., Schimek‐Jasch, T., Kremp, S., Lenz, S., Banfill, K., Davey, A., Price, G. J., Salem, A., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.004 · Cited by 53
Naci, H., Zhang, Y., Woloshin, S., Guan, X., Xu, Z., & Wagner, A. K. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00152-9 · Cited by 59
Technological advancements in antibody-based therapeutics for treatment of diseases
Lu, R., Chiang, H.-L., Yuan, J. P., Wang, H.-H., Chen, C.-Y., Panda, S. S., Liang, K.-H., Peng, H., Ko, S.-H., Hsu, H.-J., et al. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01190-2 · Cited by 68
Lee, H. J., Zeng, J., & Rengan, R. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.03.28 · Cited by 56
The Role of Surgery in Management of Locally Advanced Non-Small Cell Lung Cancer
Bryan, D. S., & Donington, J. S. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0624-7 · Cited by 52
all investigators of RTEP5 study (list in annexe), Véra, P., Mihailescu, S., Lequesne, J., Modzelewski, R., Bohn, P., Hapdey, S., Pépin, L., Dubray, B. M., Chaumet‐Riffaud, P., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04285-9 · Cited by 52
Yamaguchi, O., Kaira, K., Hashimoto, K., Mouri, A., Miura, Y., Shiono, A., Nishihara, F., Murayama, Y., Noda, S., Kato, S., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13044 · Cited by 52
ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application
Hu, G., Tu, W., Liu, Y., Peng, G., & Yang, L. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.001 · Cited by 54
Fu, J., Li, W.-Z., McGrath, N. A., Lai, C. W., Brar, G., Xiang, Y.-Q., & Xie, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650292 · Cited by 51
The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients
Yang, Y., Zhang, T., Wang, J., Wang, J., Xu, Y., Zhao, X., Ou, Q., Shao, Y. W., Wang, X., Wu, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01590-0 · Cited by 57
Rybkin, I. I., & Gadgeel, S. M. (2022) · Medical radiology · doi:10.1007/174_2022_313 · Cited by 51
Britschgi, C., Riesterer, O., Burger, I. A., Gückenberger, M., & Fontecedro, A. C. (2018) · Radiation Oncology · doi:10.1186/s13014-018-1049-3 · Cited by 50
Kaur, A., Doberstein, T., Amberker, R. R., Garje, R., Field, E. H., & Singh, N. (2019) · Medicine · doi:10.1097/md.0000000000017348 · Cited by 54
Kong, Y., Zhao, X., Xu, M., Pan, J., Ma, Y., Zou, L., Peng, Q., Zhang, J., Su, C., Xu, Z. Z., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952066 · Cited by 59
Perioperative Immune Checkpoint Inhibition in Early-Stage Non–Small Cell Lung Cancer: A Review
Desai, A. P., Adashek, J. J., Reuss, J. E., West, H., & Mansfield, A. S. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5389 · Cited by 58
Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy
Fan, S., Jiang, Z., Zhang, Z., Xing, J., Wang, D., & Tang, D. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05199-8 · Cited by 53
Small-Molecule Targets in Tumor Immunotherapy
Zhu, H., & Li, Y. (2018) · Natural Products and Bioprospecting · doi:10.1007/s13659-018-0177-7 · Cited by 51
Grassberger, C., McClatchy, D. M., Geng, C., Kamran, S. C., Fintelmann, F. J., Maruvka, Y. E., Piotrowska, Z., Willers, H., Sequist, L. V. D., Hata, A. N., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3652 · Cited by 55
Immunotherapy for Medulloblastoma: Current Perspectives
Kabir, T., Kunos, C. A., Villano, J. L., & Chauhan, A. (2020) · ImmunoTargets and Therapy · doi:10.2147/itt.s198162 · Cited by 54
Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
Banna, G. L., Cantale, O., Bersanelli, M., Re, M. D., Friedlaender, A., Cortellini, A., & Addeo, A. (2020) · Oncology Reviews · doi:10.4081/oncol.2020.490 · Cited by 59
Finn, C. F., Spigel, D. R., Senan, S., Langer, C. J., Perez, B. A., Özgüroğlu, M., Daniel, D. B., Villegas, A. E., Vicente, D., Hui, R., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.11.024 · Cited by 57
Self-citationNso, N., Antwi‐Amoabeng, D., Beutler, B. D., Ulanja, M. B., Ghuman, J., Hanfy, A. A., Nimo-Boampong, J., Atanga, S., Doshi, R. P., Enoru, S. T., et al. (2020) · World Journal of Cardiology · doi:10.4330/wjc.v12.i11.584 · Cited by 54
Metadata
- Authors
- Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y.-C., Karapetis, C. S., Hiret, S., Ostoros, G., Kubota, K., Gray, J. E., Paz-Ares, L., de Castro Carpeño, J., Wadsworth, C., Melillo, G., Jiang, H., Huang, Y., Dennis, P. A., & Özgüroğlu, M.
- Affiliations
- Institut Gustave Roussy (FR)
- From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and Florida Hospital Cancer Institute, Orlando (T.M.) — all in Florida; Tennessee Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville — both in Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de Cáncer, Universidad Complutense and...
- ORCID
- Antonia, Scott J.
- Villegas, Augusto
- Daniel, Davey
- Vicente, David
- Murakami, Shuji
- Hui, Rina
- Yokoi, Takashi
- Chiappori, Alberto
- Lee, Ki H.
- Cho, Byoung C.
- Quantin, Xavier
- Tokito, Takaaki
- Planchard, David
- Kim, Young-Chul
- Karapetis, Christos S.
- Hiret, Sandrine
- Ostoros, Gyula
- Kubota, Kaoru
- Gray, Jhanelle E.
- Paz-Ares, Luis
- Jiang, Haiyi
- Huang, Yifan
- Özgüroğlu, Mustafa
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-16
- Volume
- 377
- Issue
- 20
- Pages
- 1919-1929
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2753065806
- Cited by
- 4,593
- References
- 22
- Citations by year
- 2026: 380 · 2025: 463 · 2024: 496 · 2023: 548 · 2022: 555 · 2021: 625 · 2020: 563 · 2019: 463 · 2018: 451 · 2017: 46
- FWCI
- 183.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- HAL (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Lirias (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Cancer Research UK (20465)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- durvalumab, non-small cell lung cancer, stage III NSCLC, consolidation therapy, chemoradiotherapy, PD-L1 inhibitors, progression-free survival, overall survival, objective response rate, locally advanced unresectable lung cancer, immune checkpoint inhibitors, platinum-based chemotherapy, radiotherapy, distant metastasis, treatment safety, adverse events
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, Chemoradiotherapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.